Dyslipidemie

Why choose PRALUENT®?

Prevent the Event

Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.¹

Lipid management in patients with diabetes mellitus

Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice

A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.

Cardiovascular diseases (CVDs) are the leading cause of death globally

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

How to use PRALUENT®?

146 for Lipid Management After ACS

2024 ESC Guidelines for the management of chronic coronary syndromes

Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium

Vergoeding Praluent

Praluent is sinds 1 juni 2016 onder nadere voorwaarden vanuit de basisverzekering vergoed. Deze voorwaarden zijn vastgelegd in Bijlage 2 van de regeling zorgverzekering.